CellKey AI’s ADC Characterization Service offers a comprehensive analytical platform for evaluating the structural integrity, functional attributes, and in-plasma stability of antibody-drug conjugates (ADCs).
Utilizing advanced LC-MS/MS technology, our service provides high-resolution, quantitative analysis of ADC-related components across various biological matrices such as plasma, serum, and buffer systems.

We provide end-to-end profiling of ADCs, including:

• Total antibody quantification

• Antibody-conjugated drug (ADC) quantification

• Free payload measurement

• Plasma/serum stability testing

• Drug-to-antibody ratio (DAR) determination

• Site-specific conjugation and post-translational modification (PTM) analysis

Our analytical workflows are optimized to support CMC development, preclinical evaluation, and quality attribute monitoring for both novel ADCs and biosimilar candidates.
With extensive expertise in biologics characterization and customized method development, CellKey AI enables pharmaceutical companies to generate regulatory-compliant and publication-ready data to accelerate ADC development pipelines.

In addition to our standard service offerings, we also provide consultation and collaborative support for designing fit-for-purpose analytical strategies based on the unique properties of your ADC molecules.

Let CellKey AI help you ensure the success of your targeted therapeutic programs with accurate, high-sensitivity ADC analysis.